Lineage Cell Therapeutics, Inc. (LCTX)
Chart Events
Performance Outlook
| Previous Close | 1.3700 |
| Open | 1.3900 |
| Bid | 1.3900 x 900 |
| Ask | 1.4000 x 2900 |
| Day's Range | 1.3800 - 1.4000 |
| 52 Week Range | 1.0200 - 1.7900 |
| Volume | |
| Avg. Volume | 377,418 |
| Market Cap | 237.966M |
| Beta (5Y Monthly) | 1.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0800 |
| Earnings Date | May 10, 2023 - May 15, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
- Business Wire
RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit
CARLSBAD, Calif., March 20, 2023--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1/2a clinical study of RG6501 (OpRegen), will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit, organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute. The meeting will be held Apr
- Insider Monkey
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2022 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Welcome to the Lineage Cell Therapeutics Fourth Quarter and Full Year 2022 Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available on the Investors section of Lineage ‘s website at […]
- Thomson Reuters StreetEvents
Q4 2022 Lineage Cell Therapeutics Inc Earnings Call
Q4 2022 Lineage Cell Therapeutics Inc Earnings Call
